UroGen Pharma is trading 4.41% up now at $47.49 as investors continued reacting to August 5 earnings showing second-quarter revenue of $72.5 million, above the $62.82 million forecast.
- ZUSDURI generated $50.4 million, up 73% sequentially.
- Net loss narrowed to $0.28 per share; management raised 2026 operating-expense guidance to $260–$270 million to support the launch.